Roche Receives EU Clearance for Breakthrough Early Alzheimer's Blood Test

Swiss pharmaceutical company Roche announced Tuesday that European Union health regulators have approved its new blood test for early detection of Alzheimer's disease. This groundbreaking diagnostic tool can identify biomarkers associated with Alzheimer's before symptoms appear, potentially allowing for earlier medical intervention and treatment. The test represents a significant advancement in neurodegenerative disease detection, offering hope to millions at risk of developing the condition. Early detection enables patients and healthcare providers to plan treatment strategies and lifestyle modifications more proactively. This approval marks a major milestone in bringing precision diagnostics to Alzheimer's care across Europe.

Originally published on
Medical Xpress
Read full article(opens in new tab)Fetched: May 12, 2026 at 10:11 AM



